Clinical Trial Update: Ph 1 Study of ADI PEG 20 in Pediatric Subjects Who Are Argininosuccinate Synthetase (ASS) Deficient [Phase 1]

View source ↗

Summary

Phase 1 study of ADI-PEG 20 in pediatric patients with Argininosuccinate Synthetase Deficiency has completed. No efficacy results are provided in the summary.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Argininosuccinate Synthetase Deficiency

Drugs mentioned

• ADI-PEG 20 (pegylated arginine deiminase)

Snippet

Sponsor: Polaris Group | Conditions: Argininosuccinate Synthetase Deficient | Phase 1 | Status: COMPLETED